**Table 2**. Demographics

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Author (Year) | Journal | LoE | Sample Size (Controls) | Follow-up | Average Age (Controls) | Gender Distribution (Controls) | MINORS | Indication for Therapeutic Anticoagulation | Comorbidities |
| Aggarwal 2013[28] | JBJS American | III | 161 (161) | > 6 months | 73 (69) | 50% M 50% F  (54% M 46% F) | 71 % | AF | n/a |
| Della Valle 2020[29] | The Bone Joint Journal | III | 210 (67) | 4 months for VTE, 1 year for mortality | 69 (n/a) | 42% M 58% F (n/a) | 71 % | History of DVT, PE or both | 52% HTN, 12% Diabetes, 11.5% CAD, 7% COPD, 5% smoking, 2.5% HF |
| McDougall 2013[27] | Journal of Arthroplasty | III | 89 (179) | 1 month | 71 (71) | 53% M 47% F  (53% M 47% F) | 71 % | History of VTE, AF, cardiac valves or stents, coagulation disorders | diabetic 6% vs. 6.7% controls |
| Rhodes 2010[30] | CORR | III | 38 (39) | 3 months | 73 (65) | 47% M 53% F  (38% M 62% F) | 71 % | AF, DVT, PE, heart failure | n/a |
| Simpson 2014[26] | Journal of Arthroplasty | III | 149 (300) | 1 month | 71 (n/a) | 44% M, 56% F (n/a) | 71 % | History of VTE, AF, valves, coagulation disorders | diabetes equally distributed |
| Walton 2004[31] | Knee | III | 80 (794) | 1 year | 68 (n/a) | 34% M, 66% F (n/a) | 58% | n/a | n/a |
| *Total* | *-* | *-* | *727 (1540)* |  |  |  |  |  |  |
| LoE – level of evidence; n/a – not available; JBJS – Journal of Bone and Joint Surgery; CORR – Clinical Orthopaedics and Related Research; M – male; F – female; AF – atrial fibrillation; PE – pulmonary embolism; DVT – deep venous thrombosis; VTE – venous thromboembolism; HTN – arterial hypertension; CAD – coronary artery disease; COPD – chronic obstructive pulmonary disease; HF – heart failure; MINORS - Methodological index for non-randomized studies | | | | | | | | | |